Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.5M
Short interest
settlement 2026-10-15
10.4
Days to cover
+3.1 days vs prior
57.9%
Short share of volume
2026-11-02
485
Fails to deliver
settlement 2026-10-08
Mon 16 Nov
Next earnings
estimated date
-$226K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ORMP is 1,451,095 shares, up 143,350 shares over the last month. Over the last 48 readings it ranged from 208,680 shares (15 October 2025) to 1,451,095 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 140K shares a day that is 10.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ormp" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,451,095 | +1.2% | 139,567 | 10.40 |
| 2026-09-30 | 1,433,436 | +9.6% | 195,596 | 7.33 |
| 2026-09-15 | 1,307,745 | +13.3% | 175,933 | 7.43 |
| 2026-08-31 | 1,154,241 | +12.5% | 269,352 | 4.29 |
| 2026-08-14 | 1,025,767 | +22.8% | 175,277 | 5.85 |
| 2026-07-31 | 835,493 | +9.2% | 146,714 | 5.69 |
| 2026-07-15 | 765,356 | -12.8% | 306,923 | 2.49 |
| 2026-06-30 | 877,849 | +53.9% | 738,846 | 1.19 |
| 2026-06-15 | 570,447 | -13.5% | 187,604 | 3.04 |
| 2026-05-29 | 659,464 | +3.8% | 213,820 | 3.08 |
| 2026-05-15 | 635,431 | -2.3% | 186,020 | 3.42 |
| 2026-04-30 | 650,650 | +12.8% | 146,345 | 4.45 |
| 2026-04-15 | 576,933 | +2.5% | 97,057 | 5.94 |
| 2026-03-31 | 562,979 | +4.0% | 103,361 | 5.45 |
| 2026-03-13 | 541,599 | -2.6% | 150,797 | 3.59 |
| 2026-02-27 | 556,109 | +3.0% | 154,249 | 3.61 |
| 2026-02-13 | 540,151 | -16.2% | 143,301 | 3.77 |
| 2026-01-30 | 644,912 | +57.8% | 246,539 | 2.62 |
| 2026-01-15 | 408,588 | -3.7% | 395,056 | 1.03 |
| 2025-12-31 | 424,089 | +34.6% | 125,839 | 3.37 |
| 2025-12-15 | 315,078 | -11.8% | 191,894 | 1.64 |
| 2025-11-28 | 357,416 | +45.8% | 379,535 | 1.00 |
| 2025-11-14 | 245,076 | +1.3% | 157,408 | 1.56 |
| 2025-10-31 | 241,868 | +15.9% | 116,493 | 2.08 |
| 2025-10-15 | 208,680 | -25.6% | 115,783 | 1.80 |
| 2025-09-30 | 280,292 | +25.1% | 122,802 | 2.28 |
| 2025-09-15 | 223,986 | -35.7% | 110,956 | 2.02 |
| 2025-08-29 | 348,142 | -4.5% | 83,787 | 4.16 |
| 2025-08-15 | 364,449 | -9.8% | 63,586 | 5.73 |
| 2025-07-31 | 403,823 | -0.1% | 77,124 | 5.24 |
| 2025-07-15 | 404,343 | -3.4% | 58,913 | 6.86 |
| 2025-06-30 | 418,681 | -11.9% | 72,388 | 5.78 |
| 2025-06-13 | 475,250 | -2.9% | 90,950 | 5.23 |
| 2025-05-30 | 489,422 | -17.2% | 84,976 | 5.76 |
| 2025-05-15 | 591,029 | -9.8% | 46,043 | 12.84 |
| 2025-04-30 | 655,121 | -7.6% | 47,941 | 13.67 |
| 2025-04-15 | 708,793 | +8.9% | 99,254 | 7.14 |
| 2025-03-31 | 650,802 | -2.1% | 43,772 | 14.87 |
| 2025-03-14 | 664,591 | +7.9% | 206,318 | 3.22 |
| 2025-02-28 | 616,037 | +6.9% | 195,946 | 3.14 |
| 2025-02-14 | 576,379 | +149.0% | 855,530 | 1.00 |
| 2025-01-31 | 231,471 | -6.7% | 120,585 | 1.92 |
| 2025-01-15 | 248,149 | +2.4% | 99,578 | 2.49 |
| 2024-12-31 | 242,280 | -16.8% | 207,939 | 1.17 |
| 2024-12-13 | 291,357 | -2.7% | 272,242 | 1.07 |
| 2024-11-29 | 299,511 | -4.6% | 123,509 | 2.43 |
| 2024-11-15 | 313,896 | +4.6% | 114,540 | 2.74 |
| 2024-10-31 | 299,983 | +0.5% | 66,305 | 4.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ORMP volume is 57.9%, down 8.8 points over the last five sessions. Over the last 30 readings it ranged from 33.9% (22 September 2026) to 88.5% (2 October 2026). The latest reading is in line with the 30-session average of 56.9%, on 32K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 18K | 32K | 57.9% | 1,000 |
| 2026-10-30 | 20K | 34K | 59.3% | 0 |
| 2026-10-29 | 17K | 23K | 71.5% | 0 |
| 2026-10-28 | 9K | 17K | 55.1% | 0 |
| 2026-10-27 | 12K | 25K | 49.7% | 0 |
| 2026-10-26 | 38K | 57K | 66.7% | 0 |
| 2026-10-23 | 28K | 43K | 64.3% | 0 |
| 2026-10-22 | 18K | 38K | 48.1% | 0 |
| 2026-10-21 | 30K | 45K | 67.0% | 0 |
| 2026-10-20 | 34K | 67K | 50.1% | 0 |
| 2026-10-19 | 35K | 64K | 55.0% | 0 |
| 2026-10-16 | 39K | 89K | 43.1% | 230 |
| 2026-10-15 | 21K | 44K | 47.4% | 2 |
| 2026-10-14 | 31K | 45K | 70.0% | 0 |
| 2026-10-13 | 17K | 45K | 37.2% | 0 |
| 2026-10-12 | 13K | 24K | 52.3% | 10 |
| 2026-10-09 | 39K | 76K | 50.7% | 0 |
| 2026-10-08 | 25K | 52K | 48.8% | 900 |
| 2026-10-07 | 12K | 16K | 71.3% | 1,500 |
| 2026-10-06 | 30K | 37K | 79.5% | 5,062 |
| 2026-10-05 | 19K | 29K | 66.2% | 420 |
| 2026-10-02 | 74K | 84K | 88.5% | 0 |
| 2026-10-01 | 86K | 120K | 71.7% | 1 |
| 2026-09-30 | 19K | 42K | 45.1% | 0 |
| 2026-09-29 | 25K | 67K | 37.9% | 0 |
| 2026-09-28 | 16K | 34K | 45.1% | 0 |
| 2026-09-25 | 45K | 80K | 56.7% | 50 |
| 2026-09-24 | 24K | 46K | 51.7% | 522 |
| 2026-09-23 | 26K | 39K | 66.2% | 0 |
| 2026-09-22 | 22K | 65K | 33.9% | 800 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 October 2026, the fails-to-deliver balance in ORMP is 485 shares, up 479 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (25 September 2026) to 15,643 shares (26 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-08 | 485 | $4.37 | $2K |
| 2026-10-07 | 6 | $4.38 | $26 |
| 2026-09-25 | 2 | $4.79 | $10 |
| 2026-09-24 | 1,306 | $4.72 | $6K |
| 2026-09-21 | 685 | $4.74 | $3K |
| 2026-09-17 | 33 | $4.62 | $152 |
| 2026-09-16 | 15 | $4.62 | $69 |
| 2026-08-28 | 802 | $5.10 | $4K |
| 2026-08-27 | 4,071 | $5.34 | $22K |
| 2026-08-26 | 15,643 | $5.21 | $82K |
| 2026-08-21 | 1,987 | $4.79 | $10K |
| 2026-08-14 | 72 | $4.38 | $315 |
| 2026-08-06 | 1,186 | $4.32 | $5K |
| 2026-08-04 | 122 | $4.39 | $536 |
| 2026-07-30 | 1,126 | $3.97 | $4K |
| 2026-07-21 | 1,887 | $4.10 | $8K |
| 2026-07-17 | 1,443 | $4.05 | $6K |
| 2026-07-07 | 315 | $4.57 | $1K |
| 2026-06-30 | 11,864 | $4.64 | $55K |
| 2026-06-26 | 2,192 | $5.00 | $11K |
| 2026-06-25 | 5,209 | $4.30 | $22K |
| 2026-06-18 | 6,300 | $3.79 | $24K |
| 2026-06-17 | 4,627 | $3.77 | $17K |
| 2026-06-10 | 373 | $3.65 | $1K |
| 2026-06-09 | 1,747 | $3.64 | $6K |
| 2026-06-08 | 1,713 | $3.71 | $6K |
| 2026-06-05 | 8,273 | $3.81 | $32K |
| 2026-06-04 | 374 | $3.65 | $1K |
| 2026-06-01 | 6,000 | $3.97 | $24K |
| 2026-05-26 | 547 | $3.99 | $2K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ORMP reported 2 open-market sells worth $226K in the last 90 days and no open-market buys. Latest filing: Hexter Joshua (COO & CBO) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Hexter Joshua | COO & CBO | Sell | 30K | $4.51 | $135K | 1.3M |
| 2026-10-01 | Gabay Avraham | Chief Financial Officer | Sell | 20K | $4.51 | $90K | 861K |
| 2026-09-24 | Kidron Miriam | Chief Scientific Officer | Grant | 209K | price not stated in the filing | not stated | 1.6M |
| 2026-09-24 | Kidron Miriam | Chief Scientific Officer | Grant | 208K | price not stated in the filing | not stated | 1.3M |
| 2026-09-24 | KIDRON NADAV | President and CEO | Grant | 369K | price not stated in the filing | not stated | 4.1M |
| 2026-09-24 | KIDRON NADAV | President and CEO | Grant | 349K | price not stated in the filing | not stated | 3.8M |
| 2026-09-24 | Hexter Joshua | COO & CBO | Grant | 209K | price not stated in the filing | not stated | 1.4M |
| 2026-09-24 | Hexter Joshua | COO & CBO | Grant | 75K | price not stated in the filing | not stated | 1.1M |
| 2026-09-24 | Gabay Avraham | Chief Financial Officer | Grant | 209K | price not stated in the filing | not stated | 881K |
| 2026-07-02 | Hexter Joshua | COO & CBO | Exercise or conversion | 50K | $3.69 | $185K | 1.1M |
| 2026-07-01 | Hexter Joshua | COO & CBO | Sell | 137K | $4.46 | $611K | 1.0M |
| 2026-07-01 | Gabay Avraham | Chief Financial Officer | Sell | 73K | $4.51 | $331K | 672K |
| 2026-03-30 | Kidron Miriam | Chief Scientific Officer | Tax withholding | 435K | $3.31 | $1.4M | 1.1M |
| 2026-03-30 | KIDRON NADAV | President and CEO | Tax withholding | 45K | $3.31 | $148K | 3.4M |
| 2026-03-17 | Kidron Miriam | Chief Scientific Officer | Grant | 120K | $0.00 | $0 | 1.6M |
| 2026-03-17 | KIDRON NADAV | President and CEO | Grant | 167K | $0.00 | $0 | 3.4M |
| 2026-03-17 | Hexter Joshua | COO & CBO | Grant | 96K | $0.00 | $0 | 1.2M |
| 2026-03-17 | Gabay Avraham | Chief Financial Officer | Grant | 96K | $0.00 | $0 | 745K |
| 2026-03-12 | KIDRON NADAV | President and CEO | Gift | 100K | $0.00 | $0 | 3.3M |
| 2026-01-22 | Kidron Miriam | Chief Scientific Officer | Exercise or conversion | 19K | $0.00 | $0 | 1.4M |
| 2026-01-22 | KIDRON NADAV | President and CEO | Exercise or conversion | 109K | $0.00 | $0 | 3.4M |
| 2026-01-22 | Hexter Joshua | COO & CBO | Exercise or conversion | 19K | $0.00 | $0 | 1.1M |
| 2026-01-22 | Gabay Avraham | Chief Financial Officer | Exercise or conversion | 19K | $0.00 | $0 | 649K |
| 2026-01-14 | Kidron Miriam | Chief Scientific Officer | Gift | 86K | $0.00 | $0 | 1.3M |
| 2025-12-31 | Aghion Daniel | Director | Grant | 30K | price not stated in the filing | not stated | 107K |
| 2025-12-31 | Aghion Daniel | Director | Grant | 6K | price not stated in the filing | not stated | 113K |
| 2025-12-31 | Mayer Arie | Director | Grant | 5K | price not stated in the filing | not stated | 168K |
| 2025-12-31 | Mayer Arie | Director | Grant | 30K | price not stated in the filing | not stated | 163K |
| 2025-12-31 | Shapiro Benjamin | Director | Grant | 4K | price not stated in the filing | not stated | 123K |
| 2025-12-31 | Shapiro Benjamin | Director | Grant | 30K | price not stated in the filing | not stated | 120K |
| 2025-12-31 | Reznick Yehuda | Director | Grant | 30K | price not stated in the filing | not stated | 99K |
| 2025-12-31 | Reznick Yehuda | Director | Grant | 6K | price not stated in the filing | not stated | 105K |
| 2025-12-31 | Gabay Avraham | Chief Financial Officer | Grant | 115K | $0.00 | $0 | 630K |
| 2025-12-31 | Gabay Avraham | Chief Financial Officer | Grant | 81K | $0.00 | $0 | 515K |
| 2025-12-31 | Kidron Miriam | Chief Scientific Officer | Grant | 115K | $0.00 | $0 | 1.4M |
| 2025-12-31 | Kidron Miriam | Chief Scientific Officer | Grant | 121K | $0.00 | $0 | 1.3M |
| 2025-12-31 | KIDRON NADAV | President and CEO | Grant | 327K | $0.00 | $0 | 3.2M |
| 2025-12-31 | KIDRON NADAV | President and CEO | Grant | 233K | $0.00 | $0 | 2.9M |
| 2025-12-31 | Hexter Joshua | COO & CBO | Grant | 115K | $0.00 | $0 | 1.0M |
| 2025-12-31 | Hexter Joshua | COO & CBO | Grant | 97K | $0.00 | $0 | 930K |
| 2025-06-05 | Shapiro Benjamin | Director | Grant | 30K | price not stated in the filing | not stated | 85K |
| 2025-06-05 | Shapiro Benjamin | Director | Grant | 5K | price not stated in the filing | not stated | 90K |
| 2025-06-05 | Sank Leonard | Director | Grant | 7K | price not stated in the filing | not stated | 135K |
| 2025-06-05 | Sank Leonard | Director | Grant | 30K | price not stated in the filing | not stated | 128K |
| 2025-06-05 | Reznick Yehuda | Director | Grant | 30K | price not stated in the filing | not stated | 61K |
| 2025-06-05 | Reznick Yehuda | Director | Grant | 8K | price not stated in the filing | not stated | 69K |
| 2025-06-05 | Aghion Daniel | Director | Grant | 30K | price not stated in the filing | not stated | 69K |
| 2025-06-05 | Aghion Daniel | Director | Grant | 8K | price not stated in the filing | not stated | 77K |
| 2025-06-05 | Mayer Arie | Director | Grant | 7K | price not stated in the filing | not stated | 133K |
| 2025-06-05 | Mayer Arie | Director | Grant | 30K | price not stated in the filing | not stated | 126K |
| 2025-02-11 | Gabay Avraham | Chief Financial Officer | Grant | 42K | $0.00 | $0 | 434K |
| 2025-02-11 | Gabay Avraham | Chief Financial Officer | Grant | 34K | $0.00 | $0 | 392K |
| 2025-02-11 | KIDRON NADAV | President and CEO | Grant | 186K | $0.00 | $0 | 2.6M |
| 2025-02-11 | KIDRON NADAV | President and CEO | Grant | 141K | $0.00 | $0 | 2.4M |
| 2025-02-11 | KIDRON NADAV | President and CEO | Grant | 100K | $0.00 | $0 | 2.7M |
| 2025-02-11 | Hexter Joshua | COO & CBO | Grant | 33K | $0.00 | $0 | 833K |
| 2025-02-11 | Hexter Joshua | COO & CBO | Grant | 49K | $0.00 | $0 | 800K |
| 2025-02-11 | Hexter Joshua | COO & CBO | Grant | 45K | $0.00 | $0 | 751K |
| 2025-02-11 | Kidron Miriam | Chief Scientific Officer | Grant | 74K | $0.00 | $0 | 1.1M |
| 2025-02-11 | Kidron Miriam | Chief Scientific Officer | Grant | 52K | $0.00 | $0 | 1.1M |
| 2025-02-11 | Kidron Miriam | Chief Scientific Officer | Grant | 67K | $0.00 | $0 | 1.2M |
| 2025-01-02 | Hexter Joshua | COO & CBO | Grant | 195K | price not stated in the filing | not stated | 706K |
| 2025-01-02 | Gabay Avraham | Chief Financial Officer | Grant | 188K | price not stated in the filing | not stated | 358K |
| 2025-01-02 | KIDRON NADAV | President and CEO | Grant | 434K | price not stated in the filing | not stated | 2.3M |
| 2025-01-02 | Kidron Miriam | Chief Scientific Officer | Grant | 207K | price not stated in the filing | not stated | 1.0M |
| 2024-11-07 | Hexter Joshua | COO & CBO | Grant | 30K | price not stated in the filing | not stated | 512K |
| 2024-11-07 | Kidron Miriam | Chief Scientific Officer | Grant | 30K | price not stated in the filing | not stated | 794K |
| 2024-11-07 | KIDRON NADAV | President and CEO | Grant | 45K | price not stated in the filing | not stated | 1.8M |
| 2024-11-07 | Gabay Avraham | Chief Financial Officer | Grant | 30K | price not stated in the filing | not stated | 170K |
| 2024-06-21 | Gabay Avraham | Chief Financial Officer | Grant | 140K | price not stated in the filing | not stated | 0 |
| 2024-06-06 | Reznick Yehuda | Director | Grant | 760 | price not stated in the filing | not stated | 31K |
| 2024-04-17 | Reznick Yehuda | Director | Grant | 30K | price not stated in the filing | not stated | 30K |
| 2024-01-30 | Aghion Daniel | Director | Grant | 4K | price not stated in the filing | not stated | 39K |
| 2024-01-04 | Shapiro Benjamin | Director | Grant | 30K | price not stated in the filing | not stated | 50K |
| 2024-01-04 | Shapiro Benjamin | Director | Grant | 5K | price not stated in the filing | not stated | 55K |
| 2024-01-04 | Aghion Daniel | Director | Grant | 5K | price not stated in the filing | not stated | 35K |
| 2024-01-04 | Aghion Daniel | Director | Grant | 30K | price not stated in the filing | not stated | 30K |
| 2024-01-04 | Mayer Arie | Director | Grant | 30K | price not stated in the filing | not stated | 87K |
| 2024-01-04 | Mayer Arie | Director | Grant | 9K | price not stated in the filing | not stated | 96K |
| 2024-01-04 | Rozov Yadin | Director | Grant | 30K | price not stated in the filing | not stated | 147K |
| 2024-01-04 | Rozov Yadin | Director | Grant | 9K | price not stated in the filing | not stated | 155K |
| 2024-01-04 | Sank Leonard | Director | Grant | 9K | price not stated in the filing | not stated | 98K |
| 2024-01-04 | Sank Leonard | Director | Grant | 30K | price not stated in the filing | not stated | 89K |
| 2024-01-04 | Silberman David | Chief Financial Officer | Grant | 137K | price not stated in the filing | not stated | 367K |
| 2024-01-04 | Hexter Joshua | COO & CBO | Grant | 181K | price not stated in the filing | not stated | 482K |
| 2024-01-04 | KIDRON NADAV | President and CEO | Grant | 329K | price not stated in the filing | not stated | 1.8M |
| 2024-01-04 | Kidron Miriam | Chief Scientific Officer | Grant | 296K | price not stated in the filing | not stated | 764K |
| 2023-05-26 | Silberman David | Chief Financial Officer | Grant | 25K | price not stated in the filing | not stated | 230K |
| 2023-05-26 | Hexter Joshua | COO & CBO | Grant | 27K | price not stated in the filing | not stated | 301K |
| 2023-05-26 | Kidron Miriam | Chief Scientific Officer | Grant | 54K | price not stated in the filing | not stated | 468K |
| 2023-05-26 | Derovan Netanel | Chief Legal Officer | Grant | 21K | price not stated in the filing | not stated | 150K |
| 2023-05-26 | KIDRON NADAV | President and CEO | Grant | 120K | price not stated in the filing | not stated | 1.5M |
| 2023-05-01 | Shapiro Benjamin | Director | Grant | 20K | price not stated in the filing | not stated | 20K |
| 2023-04-17 | Mayer Arie | Director | Grant | 30K | price not stated in the filing | not stated | 57K |
| 2023-04-17 | Silberman David | Chief Financial Officer | Grant | 98K | price not stated in the filing | not stated | 206K |
| 2023-04-17 | Kidron Miriam | Chief Scientific Officer | Grant | 213K | price not stated in the filing | not stated | 415K |
| 2023-04-17 | Rozov Yadin | Director | Grant | 30K | price not stated in the filing | not stated | 117K |
| 2023-04-17 | KIDRON NADAV | President and CEO | Grant | 279K | price not stated in the filing | not stated | 1.3M |
| 2023-04-17 | Hexter Joshua | COO & CBO | Grant | 108K | price not stated in the filing | not stated | 274K |
| 2023-04-17 | Derovan Netanel | Chief Legal Officer | Grant | 81K | price not stated in the filing | not stated | 129K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for ORMP worth $1.3M at the prices reported; 2 in the last 90 days worth $234K. Latest: Joshua Hexter filed on 2026-10-01 to sell 30,000 shares ($140K) from 2026-10-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-01 | Joshua HexterOfficer | 30K | $140K | 0.072% | 2026-10-01 | Oppenheimer & Co. Inc. |
| 2026-10-01 | Avi GabayOfficer | 20K | $93K | 0.048% | 2026-10-01 | Oppenheimer & Co. Inc. |
| 2026-07-01 | Hexter JoshuaOfficer | 137K | $659K | 0.335% | 2026-07-01 | Oppenheimer & Co. Inc. |
| 2026-07-01 | Gabay AvrahamOfficer | 93K | $449K | 0.228% | 2026-07-01 | Oppenheimer & Co. Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ORMP in its latest filing, on Schedule 13G (passive). The holder is Aquamarine Financial (Cayman) Ltd at 6.0% of the class (2,512,175 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Aquamarine Financial (Cayman) Ltdother entity | 2.5M | 6.0% | 2026-06-30 |
| 2026-06-29 | 13G/Ano. 3 | Leonard Braden Michaelindividual | 1.0M | 2.5% | 2026-06-26 |
| 2026-06-29 | 13G/Ano. 3 | BML Investment Partners, L.P.partnership | 866K | 2.1% | 2026-06-26 |
13F holders
Tracked managers holding ORMP at their latest 13F. JSON3 of the 30 tracked managers held ORMP at their latest 13F, $1.2M in total at quarter-end prices. Renaissance Technologies is the largest at $884K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 184K | $884K | 0.00% | +36K |
| Citadel Advisors | 2026-06-30 | 42K | $200K | 0.00% | -57K |
| Millennium Management | 2026-06-30 | 22K | $105K | 0.00% | +6K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Oramed Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Oramed Pharmaceuticals (ORMP), SEC CIK 1176309, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2025-11-17.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1176309Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ORMP is sold short?
1,451,095 shares were held short at the 2026-10-15 settlement, 10.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ORMP's daily short volume?
On 2026-11-02, 18,450 of the 31,867 ORMP shares reported to FINRA were sold short, 57.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ORMP have fails to deliver?
The SEC's latest file shows 485 ORMP shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are ORMP insiders buying or selling?
Insiders at ORMP reported 2 open-market sells worth $226K in the last 90 days and no open-market buys. Latest filing: Hexter Joshua (COO & CBO) on 2026-10-01.
Have ORMP insiders filed to sell?
4 Form 144 notices on file for ORMP worth $1.3M at the prices reported; 2 in the last 90 days worth $234K. Latest: Joshua Hexter filed on 2026-10-01 to sell 30,000 shares ($140K) from 2026-10-01.
Who owns 5% or more of ORMP?
1 holder reports 5% or more of ORMP in its latest filing, on Schedule 13G (passive). The holder is Aquamarine Financial (Cayman) Ltd at 6.0% of the class (2,512,175 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own ORMP?
3 of the 30 tracked 13F managers held ORMP shares at their latest filing, $1.2M in all. The largest: Renaissance Technologies (184K shares, $884K), Ken Griffin's Citadel Advisors (42K shares, $200K), Izzy Englander's Millennium Management (22K shares, $105K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.